ScreenerHero
KRKKrka, d. d.
GPW · PL · Healthcare · Drug Manufacturers - Specialty & Generic · krka.biz
1120.00PLN+0.18%Mkt Cap: 8.57B $P/E: 18.81

Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Centr…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.24BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.37BUSDP/E 12.4
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.5
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.34BUSDP/E 16.6
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD
ALM
Almirall, S.A.
$2.46BUSDP/E 37.1

Key Statistics

Company
Market Cap8.57B $
Enterprise Value8.40B $
Revenue (TTM)534.84M $
Gross Profit299.61M $
Net Income (TTM)102.12M $
Revenue/Share17.60 USD
Last Price1120.00 PLN
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees13.3K
CountryPL
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINSI0031102120
Valuation
P/E (Trailing)18.81
P/E (Forward)—
PEG—
EV/EBITDA54.73
EV/Revenue15.70
P/S16.06
P/B12.99
EPS (TTM)59.44
EPS (Forward)—
52W Range
748.0082% of range1200.00
52W High1200.00 PLN
52W Low748.00 PLN
Profitability
Gross Margin57.96%
Oper. Margin28.47%
EBITDA Margin28.69%
Profit Margin19.76%
ROE17.10%
ROA13.25%
Growth
Revenue Growth5.20%
Earnings Growth63.30%
Cash Flow & Leverage
Operating CF133.88M $
CapEx (TTM)24.91M $
FCF Margin8.48%
FCF Yield0.53%
Net Debt-179.61M $
Net Debt/EBITDA-1.17
Balance Sheet
Debt/Equity0.01
Current Ratio4.21
Quick Ratio2.79
Book Value/Sh86.19 PLN
Cash/Share24.03 PLN
Dividends
Fwd Div Rate39.40 PLN
Trail. Div Rate9.100 PLN
Div. Yield3.49%
5Y Avg Yield4.95%
Payout Ratio59.96%
Ex-Div DateJul 21, 2026
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.30.28M
Float21.00M
Insiders17.65%
Institutions14.29%
Technical
SMA 501127.76 (-0.7%)
SMA 2001009.23 (+11.0%)
Beta0.44
S&P 52W Chg18.16%
Avg Vol (30d)113
Avg Vol (10d)71
Technical Indicators
RSI (14)44.9
MACD-2.0961
MACD Signal-1.2073
MACD Hist.-0.8888
BB Upper1141.33 PLN
BB Middle1126.80 PLN
BB Lower1112.27 PLN
BB Width2.58%
ATR (14)18.63 PLN
Vol Ratio (20d)1.78x